EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case-control study

Mult Scler. 2008 Sep;14(8):1120-2. doi: 10.1177/1352458508092353. Epub 2008 Jun 23.

Abstract

Objectives and methods: The interaction between the two best documented risk factors (human leukocyte antigen [HLA] class II [DRB1*1501 positivity] and Epstein-Barr virus [elevated Epstein-Barr nuclear antigen 1 (EBNA-1) antibody reactivity]) for multiple sclerosis (MS) was studied in a case-control study of biobank samples from 109 MS cases and 212 matched referents.

Results: Multivariate logistic regression analysis showed that both were statistically significant in both sexes. HLA DRB1*1501-positive referents had higher EBNA-1 reactivity than HLA-negative referents. Less EBNA-1 reactivity was required to increase the MS risk in HLA DRB1*1501-positives than in HLA-negatives.

Conclusion: We suggest that HLA DRB1*1501-positive individuals have an increased vulnerability to EBV-induced autoimmunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Epstein-Barr Virus Nuclear Antigens / blood*
  • HLA-DR Antigens / blood*
  • HLA-DRB1 Chains
  • Humans
  • Multiple Sclerosis* / epidemiology
  • Multiple Sclerosis* / immunology
  • Multiple Sclerosis* / virology
  • Multivariate Analysis
  • Risk Factors
  • Sweden / epidemiology

Substances

  • Epstein-Barr Virus Nuclear Antigens
  • HLA-DR Antigens
  • HLA-DRB1 Chains
  • HLA-DRB1*15:01 antigen
  • EBV-encoded nuclear antigen 1